The critical role of type-1 innate and acquired immunity in tumor immunotherapy

Cancer Science

Volumn 95, Issue 9, 2004, Pages 697-703

  Ikeda, Hiroaki ^a   Chamoto, Kenji ^a   Tsuji, Takemasa ^a   Suzuki, Yoshinori ^a   Wakita, Daiko ^a   Takeshima, Tsuguhide ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CYTOKINE; CYTOSINE PHOSPHOROTHIOATE GUANINE OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 12; LIPOSOME; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL INTERACTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC ENGINEERING; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TH1 CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; BIOLOGICAL RESPONSE MODIFIERS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 5044220448     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03248.x     Document Type: Review

References (57)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
2. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55: 329-33.
3. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
4. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556-61.
5. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13: 459-63.
6. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by γδ T cells. Science 2001; 294: 605-9.
7. Hayashi T, Faustman DL. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res 2002; 62: 24-7.
8. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191: 661-8.
9. Street SE, Cretney E, Smyth MJ. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97: 192-7.
10. Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M, Dranoff G. Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J Exp Med 2003; 197: 1213-9.
11. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-61.
12. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61: 274-8.
13. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10.
14. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-9.
15. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998; 187: 1163-7.
16. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
17. Dunn GP, Old LJ, Schreiber RD. The three es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
18. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7.
19. Smyth MJ, Thi KY, Street SE, MacGregor D, Godfrey DJ, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192: 755-60.
20. Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996; 26: 1844-50.
21. Engel AM, Svane IM, Rygaard J, Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 1997; 45: 463-70.
22. Ikeda H, Old LJ, Schreiber RD. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95-109.
23. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5: 508-15.
24. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46.
25. Chamoto K, Kosaka A, Tsuji T, Matsuzaki J, Sato T, Takeshima T, Iwakabe K, Togashi Y, Koda T, Nishimura T. The critical role of Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci 2003; 94: 924-8.
26. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003; 18: 367-79.
27. + regulatory T cells: their common role in controlling autommunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
28. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-42.
29. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
30. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
31. + lymphoid dendritic cells. J Exp Med 1999; 189: 1981-6.
32. + CTL. J Immunol 2001; 167: 3687-91.
33. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29: 1390-6.
34. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052-6.
35. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-20.
36. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α -galactosylceramide-loaded DCs. Nat Immunol 2002; 3: 867-74.
37. Van der Bruggen P, Traversari C, Chomoez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
38. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292-300.
39. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 745-54.
40. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman LK, Whitesel LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003; 63: 1860-4.
41. + T cells. Adv Immunol 2003; 81: 331-71.
42. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 1996; 93: 13119-24.
43. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li XF, Shimizu J, Fujiwara H, Hamaoka T. Transforming growth factor-β -induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077-82.
44. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated natural killer activity. J Immunol 1992; 148: 4072-6.
45. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
46. Ahmad-Najad P, Hacke H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-68.
47. Gursel I, Gursel M, Ishii KJ, Klinman M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001; 167: 3324-8.
48. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10: 187-92.
49. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-59.
50. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ota A, Koda T, Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46: S52-61.
51. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 1989; 57: 503-12.
52. Nishimura T, Iwakabe K, Sekimoto M, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617-28.
53. Sato M, Chamoto K, Nishimura T. A novel tumor vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific T helper type 1 cells. Int Immunol 2003; 15: 837-43.
54. Kessels HW, Wolkers MC, Van den Boom MD, Van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol 2001; 2: 957-61.
55. Chamoto K, Tsuji T, Funamoto H, Kosaka A, Matsuzaki J, Sato T, Abe H, Fujio K, Yamamoto K, Kitamura T, Takeshima T, Togashi Y, Nishimura T. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004; 64: 386-90.
56. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-4.
57. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, Miyoshi H, Kawarada Y, Katoh H, Takeshima T, Nishimura T. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T cell receptor. Cancer Res 2004; 64: 1490-5.